Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Common Variable Immunodeficiency (CVID) in Adults As First Manifestation of (cryptic) Dyskeratosis Congenita

Benjamin Rolles, MD, Alla Bulashevska, PhD, Michele Proietti, MD, Sigune Goldacker, MD, Klaus Warnatz, MD, Nadezhda Camacho-Ordonez, MD, Margherita Vieri, MSc, Martin Kirschner, MD, Tim H Brümmendorf, MD, Bodo Grimbacher, MD, Fabian Beier, MD

Blood (2019) 134 (Supplement_1): 1217.

https://doi.org/10.1182/blood-2019-128915

Published: 2019

Journal Articles

Clinical Spectrum of Patients with Pathogenic Variant of STAT3 conferring Gain-of-Function: A Mimic of Autoimmune Lymphoproliferative Syndrome

Gregory Constantine, MD, Helen Su, MD, PhD, Les Folio, MD, Joshua Milner, MD, V. Koneti Rao, MD FRCPA

Blood (2018) 132 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2018-99-111950

Published: 2018

Journal Articles

The Management of Relapsed Hodgkin´s Lymphoma after Haploidentical Stem Cell Transplantation: Donnor Lymphocyte Infusion and Brentuximab Vedotin

Alejandro Contento-Gonzalo, MD, Irene Sánchez-Bazán, MD, Daniel Barrios-Decoud, Maria Magdalena Alcalá-Peña, Maria Jesus Pascual-Cascon, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 5502.

https://doi.org/10.1182/blood.V130.Suppl_1.5502.5502

Published: 2017

Journal Articles

Pulmonary Hypertension and Associated Risk Factors in a High Burden Sickle Cell Disease Population

Jane Sandra Afriyie-Mensah, Yvonne Adomakoh, MBBS, Audrey Forson, MBChB, Adadey Martin, MBChB, Joseph Acquaye, MBBS

Blood (2017) 130 (Supplement 1): 2261.

https://doi.org/10.1182/blood.V130.Suppl_1.2261.2261

Published: 2017

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John D. Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael Tarantino, Nicola Cooper, MA, MD MRCP, FRCPath, Donald Beam, Jenny M. Despotovic, DO, MS, Alexey Maschan, MD PhD Professor, Nancy Carpenter, Melissa Eisen, Joseph Park

Blood (2017) 130 (Supplement 1): 2334.

https://doi.org/10.1182/blood.V130.Suppl_1.2334.2334

Published: 2017

Journal Articles

Heterozygous RTEL1 Variants Are Associated with Bone Marrow Failure and Abnormal Clinical Phenotype

Shreyans Gandhi, MD DNB, MRCP, FRCPath, Jie Jiang, Mariam Ibanez, Isabelle Callebaut, Judith CW Marsh, Ghulam J Mufti, MD

Blood (2016) 128 (22): 1043.

https://doi.org/10.1182/blood.V128.22.1043.1043

Published: 2016

Journal Articles

TP53 Mutation in Waldenstrom Macroglobulinemia

Stephanie Poulain, Christophe Roumier, MD, Elisabeth Bertrand, Aline Renneville, MD, Sabine Tricot, Aurelie Caillault Venet, Sandrine Geffroy, PhD, Morgan Nudel, Charles Herbaux, MD, Stéphanie Guidez, Claude Preudhomme, MD PhD, Xavier Leleu

Blood (2016) 128 (22): 4092.

https://doi.org/10.1182/blood.V128.22.4092.4092

Published: 2016

Journal Articles

A Prospective Study of Thyomosin α1 and Intravenous Immunoglobulin Role to Prevent the Infectious Pneumonia Related to Rituximab Based Immuno-Chemotherapy for B Cell Lymphoma

Tongyu Lin, Raj Shrestha Prem, He Huang, Xueying Li, Huangming Hong, Mengping Zhang, Xiaojie Fang, Zhao Wang, Chengcheng Guo, Zhongjun Xia, MD

Blood (2016) 128 (22): 5394.

https://doi.org/10.1182/blood.V128.22.5394.5394

Published: 2016

Journal Articles

Incidence, Risk Factors and Outcome of Late Onset Noninfectious Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study

Anne Bergeron, MD PhD, Sylvie Chevret, MD PhD, Regis Peffault De La Tour, MD PhD, Karine Chagnon, MD, Cedric De Bazelaire, MD PhD, Frédéric Rivière, MD, Marie Robin, MD PhD, Jean Mani, MD, Gwenael Lorillon, MD, Socié Gérard, MD PhD, Abdellatif Tazi, MD PhD

Blood (2016) 128 (22): 4562.

https://doi.org/10.1182/blood.V128.22.4562.4562

Published: 2016

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, James B. Bussel, MD, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, MD PhD, Nancy Carpenter, Melissa Eisen, Bhakti Mehta

Blood (2016) 128 (22): 869.

https://doi.org/10.1182/blood.V128.22.869.869

Published: 2016

Journal Articles

Large Granular Lymphocyte Infiltration in the Bone Marrow in Children and Young Adults May Suggest Primary Immune Deficiency

Mervi H Taskinen, MD PhD, Satu Mustjoki, MD PhD, Kirsi Jahnukainen, MD PhD, Luca Trotta, MSc, Timo Siitonen, MD PhD, Timo Hautala, MD PhD, Andrey Zavialov, PhD, Kaarina Heiskanen, MD PhD, Emma M Haapaniemi, MD PhD, Janna Saarela, MD PhD, Mikko Seppänen, MD PhD

Blood (2015) 126 (23): 1024.

https://doi.org/10.1182/blood.V126.23.1024.1024

Published: 2015

Journal Articles

Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)

Blood (2015) 126 (23): 397.

https://doi.org/10.1182/blood.V126.23.397.397

Published: 2015

Journal Articles

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

Wei Ding, MD PhD, Haidong Dong, MD PhD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Betsy R. Laplant, MS, Rong He, MD, Thomas E. Witzig, MD, Yi Lin, MD PhD, Asher Chanan-Khan, MD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Thomas M. Habermann, MD, David Viswanatha, MD, Ivana Micallef, MD, Neil E. Kay, MD, Stephen Ansell, MD PhD

Blood (2015) 126 (23): 834.

https://doi.org/10.1182/blood.V126.23.834.834

Published: 2015

Journal Articles

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Craig H. Moskowitz, MD, Vincent Ribrag, MD, Jean-Marie Michot, MD, Giovanni Martinelli, MD, Pier Luigi Zinzani, MD, PhD, Martin Gutierrez, MD, Guadalupe De Maeyer, Alexandra G. Jacob, BS, Karen Giallella, Jennifer Weimer Anderson, Martha Derosier, Joy Wang, Zijiang Yang, Eric Rubin, MD, Shelonitda Rose, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2014) 124 (21): 290.

https://doi.org/10.1182/blood.V124.21.290.290

Published: 2014

Journal Articles

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, MD, Sven de Vos, MD PhD, Jacqueline C. Barrientos, MD, Marshall T. Schreeder, MD, Ian W. Flinn, MD PhD, Jeff P. Sharman, MD, Thomas E Boyd, MD, Nathan Fowler, MD, John P. Leonard, MD, Kanti R. Rai, MD, Yeonhee Kim, PhD, Anthony Viggiano, MS, Thomas M. Jahn, MD PhD, Steven E. Coutre, MD

Blood (2014) 124 (21): 5653.

https://doi.org/10.1182/blood.V124.21.5653.5653

Published: 2014

Journal Articles

Defect in B Cell Production Driven By GATA2 Mutation Results in Their Absolute Reduction and Mature Phenotype in Pediatric Patients

Michaela Novakova, Ales Janda, Marcin W Wlodarski, Martina Sukova, Vit Campr, Marketa Kubricanova Zaliova, Eva Fronkova, Elena Vodickova, Ondrej Zapletal, Jan Blatny, Katerina Lejhancova, Dagmar Pospisilova, Zdena Cerna, Tomas Kuhn, Zuzana Zemanova, Jan Trka, Ondrej Hrusak, Jan Stary, Ester Mejstrikova

Blood (2014) 124 (21): 2746.

https://doi.org/10.1182/blood.V124.21.2746.2746

Published: 2014

NARROW

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Common Variable Immunodeficiency (CVID) in Adults As First Manifestation of (cryptic) Dyskeratosis Congenita

Clinical Spectrum of Patients with Pathogenic Variant of STAT3 conferring Gain-of-Function: A Mimic of Autoimmune Lymphoproliferative Syndrome

The Management of Relapsed Hodgkin´s Lymphoma after Haploidentical Stem Cell Transplantation: Donnor Lymphocyte Infusion and Brentuximab Vedotin

Pulmonary Hypertension and Associated Risk Factors in a High Burden Sickle Cell Disease Population

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Heterozygous RTEL1 Variants Are Associated with Bone Marrow Failure and Abnormal Clinical Phenotype

TP53 Mutation in Waldenstrom Macroglobulinemia

A Prospective Study of Thyomosin α1 and Intravenous Immunoglobulin Role to Prevent the Infectious Pneumonia Related to Rituximab Based Immuno-Chemotherapy for B Cell Lymphoma

Incidence, Risk Factors and Outcome of Late Onset Noninfectious Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Large Granular Lymphocyte Infiltration in the Bone Marrow in Children and Young Adults May Suggest Primary Immune Deficiency

Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study)

PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485)

PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)

Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Defect in B Cell Production Driven By GATA2 Mutation Results in Their Absolute Reduction and Mature Phenotype in Pediatric Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only